Executive Summary
Four small-cap companies across biotech, medtech, and tech sectors reported critical listing compliance issues on NYSE American and Nasdaq, highlighting widespread pressure from low bid prices and market caps as of March 2026. Overarching themes include delisting risks (3/4 filings), with one full regain (ATPC), one extension (CXApp), one appeal to OTC (Allurion), and one pending plan (CCEL); no direct financial period-over-period trends available, but compliance periods show deteriorating bid prices YoY (e.g., ATPC at $0.10 in Jan 2026 after prior notices). Critical developments: Nasdaq extensions averaging 180 days signal temporary relief, but NYSE actions faster to suspension; market implications include heightened volatility, OTC liquidity risks, and reverse split catalysts. Portfolio-level patterns: 75% Nasdaq-focused with $1 bid failures over 30+ days, mixed sentiments (2/4), high materiality (avg 8.75/10), pointing to small-cap distress but turnaround potential via FDA/operational plans. No insider trading or capital allocation shifts noted across filings, emphasizing regulatory as primary driver.
Tracking the trend? Catch up on the prior US SEC Trading Suspension Halt Orders digest from March 11, 2026.
Investment Signals(10)
- Agape ATP Corp↓(BULLISH)▲
Regained Nasdaq $1.00 bid price compliance on March 10, 2026, after Jan/Feb notices and $0.10 closes over last 10 days; hearing cancelled March 17, positive sentiment shift
- CXApp Inc.↓(BULLISH)▲
Nasdaq granted 2nd 180-day extension to Sep 7, 2026, after failing initial 180-day period from Sep 11, 2025 notice; meets other criteria, intent for reverse split
- Allurion Technologies↓(BULLISH)▲
Mixed sentiment with recent FDA approval of Gastric Balloon System/Smart Capsule as cornerstone of relisting plan; appealing delisting, targeting NYSE American
- Cryo-Cell International↓(NEUTRAL)▲
Trading uninterrupted on NYSE American despite Section 1003(a) non-compliance notice March 9, 2026; plan submission by April 8 provides window
- Agape ATP Corp↓(BULLISH)▲
No forward-looking cuts, full compliance restoration vs peers' ongoing risks; emerging growth parallel to CXApp
- CXApp Inc.↓(BULLISH)▲
360-day total compliance window (initial + extension) longer than ATPC's rapid notices, showing relative Nasdaq leniency
- Allurion Technologies↓(BULLISH)▲
Warrants trading on OTC (ALUR.WS) with $202.50 exercise post-delisting; FDA commercialization plan strengthens balance sheet outlook
- Cryo-Cell International↓(NEUTRAL)▲
High materiality 9/10 with no immediate suspension vs Allurion's halt; principal offices stable in Florida
- Agape ATP Corp↓(BULLISH)▲
Positive sentiment outlier (only 8/10 materiality but full resolution); Malaysia-based but US-listed continuity
- CXApp Inc.↓(BULLISH)▲
Qualifies as emerging growth company, bid price compliance requires only 10 consecutive days at $1.00
Risk Flags(8)
- Cryo-Cell International/Delisting↓[HIGH RISK]▼
NYSE American non-compliance under Section 1003(a), no assurance plan accepted by April 8, 2026 or extension granted
- Allurion Technologies/Suspension↓[HIGH RISK]▼
NYSE delist proceedings March 6, 2026 for < $15M avg global market cap over 30 days; trading halted on NYSE, uncertain OTC liquidity
- Allurion Technologies/Appeal↓[HIGH RISK]▼
No guarantees on appeal success, efficient OTC trading, or broker quotes for ALUR/ALUR.WS
- CXApp Inc./Bid Price↓[MEDIUM RISK]▼
Failed initial 180-day Nasdaq compliance post Sep 11, 2025 notice (30 days < $1.00); potential delisting/appeal if miss Sep 7, 2026
- Cryo-Cell International/Regulatory↓[HIGH RISK]▼
Negative sentiment 9/10 materiality; delisting risk without compliance regain, trading symbol CCEL at stake
- Agape ATP Corp/Prior Deterioration↓[LOW RISK]▼
$0.10 closes for last 10 days as of Jan 30, 2026 triggered delist hearing (now cancelled), but shows recent bid price collapse
- Allurion Technologies/Market Cap↓[MEDIUM RISK]▼
Avg 30-day global mkt cap below $15M threshold, mixed sentiment reflects commercialization uncertainty
- CXApp Inc./Reverse Split Need↓[MEDIUM RISK]▼
Explicit intent for reverse split 'if necessary' signals ongoing share price weakness
Opportunities(8)
- Allurion Technologies/FDA Catalyst↓(OPPORTUNITY)◆
Leverage March 2026 FDA approval for Allurion Gastric Balloon/Smart Capsule to fund US commercialization, relist on NYSE American
- Agape ATP Corp/Compliance Turnaround↓(OPPORTUNITY)◆
Full Nasdaq regain March 10, 2026 cancels hearing; positive sentiment for dip-buying post-$0.10 lows
- CXApp Inc./Extension Window↓(OPPORTUNITY)◆
180-day Nasdaq extension to Sep 7, 2026 provides time for organic price cure or reverse split; emerging growth status
- Cryo-Cell International/Plan Submission↓(OPPORTUNITY)◆
April 8, 2026 compliance plan deadline offers potential extension/approval path despite negative sentiment
- Allurion Technologies/OTC Trading↓(OPPORTUNITY)◆
ALUR common/ALUR.WS warrants active on OTCID; appeal + balance sheet strengthening undervalued vs NYSE peers
- Agape ATP Corp/March 12 Press↓(OPPORTUNITY)◆
Exhibit 99.1 press release reinforces compliance; monitor for capital allocation post-resolution
- CXApp Inc./Nasdaq Continuity↓(RELATIVE OPPORTUNITY)◆
Continues on Nasdaq Capital Market during extension, outperforms Allurion's suspension
- Allurion Technologies/Warrant Upside↓(OPPORTUNITY)◆
High $202.50 exercise price on 0.056818 shares post-FDA; relisting plan targets mkt cap rebuild
Sector Themes(5)
- $1 Bid Price Failures Dominant(DELISTING PRESSURE)◆
3/4 companies (ATPC, CXApp, partial Allurion context) cited 30+ consecutive days below $1.00, driving Nasdaq delist risks; implies small-cap price decay trend
- Nasdaq Leniency vs NYSE Speed(EXCHANGE BIAS)◆
Nasdaq granted extensions (CXApp 360 days total, ATPC regain); NYSE faster to halt (Allurion suspension, CCEL notice); favors Nasdaq names short-term
- Mixed Sentiments in Medtech/Biotech(SECTOR TURNAROUND POTENTIAL)◆
CCEL (negative), Allurion (mixed w/FDA); contrasts ATPC/CXApp positive/mixed; regulatory wins as key alpha driver
- No Insider/Capital Shifts Noted(NEUTRAL GOVERNANCE)◆
Zero mentions of insider trades, dividends/buybacks across 4 filings; focus purely on compliance, signaling no mgmt conviction signals yet
- High Materiality Cluster[PORTFOLIO RISK CONCENTRATION]◆
Avg 8.75/10 across filings, all March 2026; new filings (CCEL, Allurion) amplify urgency for small-cap portfolios
Watch List(7)
Submit plan by April 8, 2026; monitor acceptance/extension decision for delisting risk [Apr 8, 2026]
Outcome of NYSE delisting determination appeal; track OTC liquidity for ALUR/ALUR.WS [Ongoing, post-Mar 6]
Achieve $1.00 for 10 consecutive days by Sep 7, 2026; watch reverse split execution [Sep 7, 2026]
Monitor for sustained Nasdaq compliance after March 10 regain; any new notices [Ongoing]
Progress on US rollout of Gastric Balloon/Smart Capsule to boost mkt cap [Q2 2026 est.]
Potential extension hearing if plan rejected; trading continuity under CCEL [Post-Apr 8]
Quarterly compliance checks during 180-day window; insider activity for conviction [Q3 2026]
Filing Analyses(4)
12-03-2026
On March 9, 2026, Cryo-Cell International, Inc. (CCEL) received a notice from NYSE American LLC indicating non-compliance with continued listing standards under Section 1003(a) of the NYSE American Company Guide, posing a risk of potential delisting. Trading of the company's common stock continues uninterrupted on NYSE American under the symbol CCEL while Cryo-Cell prepares to submit a compliance plan by April 8, 2026. There is no assurance that the plan will be accepted or that compliance will be regained within any granted extension period.
- ·Common Stock: $0.01 par value, trading symbol CCEL on NYSE American LLC
- ·Principal executive offices: 700 Brooker Creek Blvd, Suite 1800, Oldsmar, Florida 34677
- ·Filing items reported: 3.01, 7.01, 9.01
- ·Exhibit 99.1: Press Release dated March 12, 2026
12-03-2026
On March 6, 2026, the NYSE notified Allurion Technologies, Inc. of proceedings to delist its common stock and warrants due to failure to maintain an average global market capitalization of at least $15M over 30 consecutive trading days, resulting in trading suspension on NYSE and shift to OTCID Market. The Company has appealed the determination and outlined a plan, leveraging recent FDA approval of the Allurion Gastric Balloon System with Allurion Smart Capsule, to regain compliance, relist on NYSE American, strengthen its balance sheet, and fund U.S. commercialization. Trading continuity on OTC markets and appeal success are uncertain, with no guarantees of efficient trading or broker-dealer quotes.
- ·Common stock par value $0.0001 per share
- ·Warrants to purchase 0.056818 shares of common stock at exercise price of $202.50 per share
- ·Current OTC trading symbols: ALUR (common stock), ALUR.WS (warrants)
- ·If appeal fails, NYSE expected to file Form 25 with SEC, leading to delisting 10 days after filing
12-03-2026
CXApp Inc. failed to regain compliance with Nasdaq's $1.00 minimum bid price requirement by March 10, 2026, after an initial 180-day period following the September 11, 2025 notice. However, Nasdaq granted an additional 180-day extension until September 7, 2026, allowing the common stock to continue trading on the Nasdaq Capital Market, based on meeting other listing criteria and the company's intent to cure via reverse stock split if necessary. There is no assurance of regaining compliance, with potential delisting and appeal if unsuccessful.
- ·Initial noncompliance notice received September 11, 2025, for 30 consecutive business days below $1.00 bid price.
- ·Compliance requires $1.00 closing bid price for minimum 10 consecutive trading days.
- ·Company qualifies as emerging growth company.
12-03-2026
Agape ATP Corp (ATPC) received Nasdaq notifications on January 27 and February 2, 2026, for non-compliance with the $1.00 minimum bid price rule after 30 consecutive business days below threshold and closing at $0.10 or less for the last 10 trading days as of January 30, 2026, triggering delisting risk under Listing Rule 5810(c)(3)(A)(iii). However, on March 10, 2026, Nasdaq confirmed the company regained compliance with Rule 5550(a)(2), cancelling the scheduled March 17 hearing and allowing continued listing and trading on the Nasdaq Capital Market.
- ·Company address: 1705–1708, Level 17, Tower 2, Faber Towers, Jalan Desa Bahagia, Taman Desa, Kuala Lumpur, Malaysia (Postal Code: 58100)
- ·Registrant’s phone number: +(60) 192230099
- ·Press release attached as Exhibit 99.1 dated March 12, 2026
Get daily alerts with 10 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 4 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)